GOLD 2027更新解读:慢阻肺病管理迈向“早识别、早发现、更精准、更综合”
导语:GOLD 2027:于旧章之上添新页,慢阻肺病管理再进一步。
新增专章:GOLD 与 GINA 共同愿景,把慢阻肺病纳入全球健康优先议程
定义与评估:四个术语厘清边界,CT 与“黏液栓塞”推动早发现
保留比值受损肺量计(PRISm):舒张后FEV1/FVC≥0.70,但FEV1低于预计值的80%; 临界气流受限:舒张后FEV1/FVC≥0.70但低于正常下限(LLN),或舒张前<0.70而舒张后≥0.70; CT显示肺气肿或气道壁增厚,肺功能未阻塞,但影像已有结构异常; 伴慢性咳嗽咳痰的吸烟者或生物燃料暴露者,症状与暴露背景明确,肺功能尚未阻塞; 单纯一氧化碳弥散量(DLCO)减低的吸烟者或生物燃料暴露者; 肺功能加速下降的吸烟者或生物燃料暴露者:FEV1年下降约30~40 mL。
治疗更新:A组初始方案明确LAMA,生物治疗与非药物管理并行
ETHOS研究中,固定三联较LABA/LAMA降低中重度急性加重率24%,全因死亡风险降低46%[4]; KRONOS研究中,固定三联在24周随访中较LABA/LAMA降低中重度急性加重率52%[5]; IMPACT研究中,固定三联较LABA/LAMA降低中重度急性加重率25%,并可降低42%全因死亡风险[6]。
管理维度扩展:加重后心血管风险、共病细化与AI赋能
小结
参考文献:
[1]Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of COPD: 2027 Report. GOLD-Report-2027-FINAL-v1.0-15Nov2026.
[2]Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet. 2018 Apr 28;391(10131):1706-1717.
[3]Halpin DMG, Masekela R, Vogelmeier CF, et al. Addressing the Global Challenges of COPD and Asthma: A Shared Vision from the Global Initiative for Chronic Obstructive Pulmonary Disease (GOLD) and the Global Initiative for Asthma (GINA). Arch Bronconeumol. 2026 Feb;62(2):113-117.
[4]Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383(1):35-48.
[5]Muro S, Kawayama T, Sugiura H, et al. Benefits of budesonide/glycopyrronium/formoterol fumarate dihydrate on lung function and exacerbations of COPD: a post-hoc analysis of the KRONOS study by blood eosinophil level and exacerbation history. Respir Res. 2024 Aug 5;25(1):297.
[6]Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671-1680.
*“医学界”力求所发表内容专业、可靠,但不对内容的准确性做出承诺;请相关各方在采用或以此作为决策依据时另行核查。
文章原文
内容来自 医学界,版权归原作者所有。
阅读原文 ↗